The effects of ergot and non-ergot-derived dopamine agonists in an experimental mouse model of endometriosis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Implantation of a retrogradely shed endometrium during menstruation requires an adequate blood supply, which allows the growth of endometriotic lesions. This suggests that the development of endometriosis can be impaired by inhibiting angiogenesis. The growth of endometriotic foci is impaired by commercial oncological antiangiogenic drugs used to block vascular endothelial growth factor (VEGF) signaling. The dopamine agonist cabergoline (Cb2) inhibits the growth of established endometriosis lesions by exerting antiangiogenic effects through VEGFR2 inactivation. However, the use of ergot-derived Cb2 is associated with an increased incidence of cardiac valve regurgitation. To evaluate the potential usage of non-ergot-derived dopamine agonists for the treatment of human endometriosis, we compared the efficacy of quinagolide with that of Cb2 in preventing angiogenesis and vascularization in a heterologous mouse model of endometriosis. Nude mice whose peritoneum had been implanted with eutopic human endometrial fragments were treated with vehicle, 50 μg/kg per day oral Cb2, or 50 or 200 μg/kg per day quinagolide during a 14-day period. At the end of the treatment period, the implants were excised in order to assess lesion size, cell proliferation, degree of vascularization, and angiogenic gene expression. Neoangiogenesis was inhibited and the size of active endometriotic lesions, cellular proliferation index, and angiogenic gene expression were significantly reduced by both dopamine agonists when compared with the placebo. Given that Cb2 and quinagolide were equally effective in inhibiting angiogenesis and reducing lesion size, these experiments provide the rationale for pilot studies to explore the use of non-ergot-derived dopamine agonists for the treatment of endometriosis in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular endothelial growth factor (VEGF) in endometriosis
Donnez, J., Smoes, P., Gillerot, S., Casanas-Roux, F., & Nisolle, M. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1686 · Cited by 531 · cited 1×
“…a rich vascularized area; this can be observed under histological examination (Nisolle et al. 1993, Nap et al. 2004) and confirms the essential role that angiogenesis plays in the development and continuation of endometriotic lesions (Shifren et al. 1996, Donnez et al. 1998, Becker et al. 2005).”
BackgroundDrugs and Valvular Heart Disease
Roth, B. L. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068265 · Cited by 479 · cited 2×
“Unlike Cb2, quinagolide is unlikely to affect cardiac valve tissue and, www.reproduction-online.org therefore, is not expected to induce proliferation of fibroblasts (Roth 2007) or regurgitation.”
BackgroundWalch, K., Unfried, G., Huber, J., Kurz, C., van Trotsenburg, M., Pernicka, E., & Wenzl, R. (2009) · Contraception · doi:10.1016/j.contraception.2008.07.017 · Cited by 128
Cited by
New developments in the medical treatment of endometriosis
Bedaiwy, M. A., Alfaraj, S., Yong, P., & Casper, R. (2017) · Fertility and Sterility · doi:10.1016/j.fertnstert.2016.12.025 · Cited by 176
Medical Management of Endometriosis
RAFIQUE, S., & DECHERNEY, A. H. (2017) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000292 · Cited by 173
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
From pathogenesis to clinical practice: Emerging medical treatments for endometriosis
Clemenza, S., Sorbi, F., Noci, I., Capezzuoli, T., Turrini, I., Carriero, C., Buffi, N., Fambrini, M., & Petraglia, F. (2018) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2018.01.021 · Cited by 63
New trends for the medical treatment of endometriosis
Rocha, A. L. L., Reis, F. M., & Petraglia, F. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.683783 · Cited by 60
Metadata
- Authors
- Delgado-Rosas, F., Gómez, R., Ferrero, H., Gaytan, F., Garcia-Velasco, J., Simón, C., & Pellicer, A.
- Venue
- Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-11-01
- Volume
- 142
- Issue
- 5
- Pages
- 745-755
- ISSN
- 1470-1626 (ISSN-L)
- 1741-7899
- OpenAlex
- W2115056064
- Cited by
- 78
- References
- 3
- FWCI
- 5.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.